Subcellular mislocalization of mutant hepatitis B X proteins contributes to modulation of stat/socs signaling in hepatocellular carcinoma

Intervirology

Volumn 51, Issue 6, 2009, Pages 432-443

  Bock, C Thomas ^a   Toan, Nguyen L ^a,b   Koeberlein, Bernd ^a   Song, Le H ^c   Chin, Ruth ^d   Zentgraf, Hanswalter ^e   Kandolf, Reinhard ^a   Torresi, Joseph ^d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Medical University   (Poland)

^c Tran Hung Dao Hospital   (Viet Nam)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cell signaling; Chronic hepatitis; Hepatitis B replication; Hepatocarcinogenesis; Virus variants

Indexed keywords

HEPATITIS B X PROTEIN; MUTANT PROTEIN; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HUMAN; IMMUNOFLUORESCENCE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; VIRUS INFECTION; WESTERN BLOTTING; WILD TYPE;

ADULT; AGED; AMINO ACID SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; MUTATION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TIME FACTORS; TRANS-ACTIVATORS;

HEPATITIS B VIRUS;

EID: 62849115345     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209672     Document Type: Article

References (53)

1. Feitelson MA, Reis HM, Liu J, Lian Z, Pan J: Hepatitis B virus X antigen (HBxAg) and cell cycle control in chronic infection and hepatocarcinogenesis. Front Biosci 2005; 10: 1558-1572.
2. Bouchard MJ, Schneider RJ: The enigmatic X gene of hepatitis B virus. J Virol 2004; 78: 12725-12734.
3. Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH: Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993; 361: 742-745.
4. Kim CM, Koike K, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320.
5. Benn J, Su F, Doria M, Schneider RJ: Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal- regulated and c-Jun N-terminal mitogen- activated protein kinases. J Virol 1996; 70: 4978-4985.
6. Andrisani OM, Barnabas S: The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis. Int J Oncol 1999; 15: 373-379.
7. Su F, Schneider RJ: Hepatitis B virus HBx protein activates transcription factor NF- - B by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol 1996; 70: 4558- 4566.
8. Benn J, Schneider RJ: Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994; 91: 10350-10354.
9. Tarn C, Zou L, Hullinger RL, Andrisani OM: Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J Virol 2002; 76: 9763-9772.
10. Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL: Hepatitis B virus X protein inhibits transforming growth factor- -induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem 2000; 275: 25858-25864.
11. Lee YH, Yun Y: HBx protein of hepatitis B virus activates JAK1-STAT signaling. J Biol Chem 1998; 273: 25510-25515.
12. Waris G, Huh KW, Siddiqui A: Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF- B via oxidative stress. Mol Cell Biol 2001; 21: 7721-7730.
13. Poussin K, Dienes H, Sirma H, Urban S, Beaugrand M, Franco D, et al: Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer 1999; 80: 497-505.
14. Tu H, Bonura C, Giannini C, Mouly H, Soussan P, Kew M, et al: Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001; 61: 7803-7810.
15. Yeh CT, Shen CH, Tai DI, Chu CM, Liaw YF: Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 2000; 19: 5213-5220.
16. Hsia CC, Yuwen H, Tabor E: Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet 1996; 348: 625-626.
17. Takahashi K, Akahane Y, Hino K, Ohta Y, Mishiro S: Hepatitis B virus genomic sequence in the circulation of hepatocellular carcinoma patients: comparative analysis of 40 full-length isolates. Arch Virol 1998; 143: 2313-2326.
18. Henkler F, Hoare J, Waseem N, Goldin RD, McGarvey MJ, Koshy R, et al: Intracellular localization of the hepatitis B virus HBx protein. J Gen Virol 2001; 82: 871-882.
19. Darnell JE Jr: STATs and gene regulation. Science 1997; 277: 1630-1635.
20. Zhong Z, Wen Z, Darnell JE Jr: Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994; 264: 95-98.
21. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al: Demonstration of an interferon- dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95: 7556-7561.
22. Yu H, Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
23. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al: Stat3 as an oncogene. Cell 1999; 98: 295-303.
24. Darnell JE: Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595-596.
25. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene 2000; 19: 2474-2488.
26. Alexander WS: Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002; 2: 410-416.
27. Krebs DL, Hilton DJ: SOCS proteins: negative regulators of cytokine signaling. Stem Cells 2001; 19: 378-387.
28. Ogata H, Chinen T, Yoshida T, Kinjyo I, Takaesu G, Shiraishi H, et al: Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF- 1 production. Oncogene 2006; 25: 2520-2530.
29. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, et al: Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006; 131: 179-193.
30. Song lH, Binh VQ, Duy DN, Juliger S, Bock TC, Luty AJ, et al: Mannose-binding lectin gene polymorphisms and hepatitis B virus infection in Vietnamese patients. Mutat Res 2003; 522: 119-125.
31. Song LH, Duy DN, Binh VQ, Luty AJ, Kremsner PG, Bock CT: Low frequency of mutations in the X gene, core promoter and precore region of hepatitis B virus infected Vietnamese. J Viral Hepat 2005; 12: 160-167.
32. Toan NL, Song lH, Kremsner PG, Duy DN, Binh VQ, Koeberlein B, et al: Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology 2006; 43: 1375-1384.
33. Bock CT, Malek NP, Tillmann HL, Manns MP, Trautwein C: The enhancer I core region contributes to the replication level of hepatitis B virus in vivo and in vitro. J Virol 2000; 74: 2193-2202.
34. Bock CT, Tillmann HL, Maschek HJ, Manns MP: A PreS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 1997; 113: 1976-1982.
35. Doria M, Klein N, Lucito R, Schneider RJ: The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 1995; 14: 4747-4757.
36. Li WC, Ye SL, Sun RX, Liu YK, Tang ZY, Kim Y, et al: Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 2006; 12: 7140-7148.
37. Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, et al: Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293: 300-303.
38. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C: Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18: 4848-4859.
39. Kumar V, Jayasuryan N, Kumar R: A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function. Proc Natl Acad Sci USA 1996; 93: 5647-5652.
40. Noh EJ, Jung HJ, Jeong G, Choi KS, Park HJ, Lee CH, et al: Subcellular localization and transcriptional repressor activity of HBx on p21(WAF1/Cip1) promoter is regulated by ERK-mediated phosphorylation. Biochem Biophys Res Commun 2004; 319: 738-745.
41. Forgues M, Marrogi AJ, Spillare EA, Wu CG, Yang Q, Yoshida M, et al: Interaction of the hepatitis B virus X protein with the Crm1- dependent nuclear export pathway. J Biol Chem 2001; 276: 22797-22803.
42. Majano P, Lara-Pezzi E, Lopez-Cabrera M, Apolinario A, Moreno-Otero R, Garcia- Monzon C: Hepatitis B virus X protein transactivates inducible nitric oxide synthase gene promoter through the proximal nuclear factor- B-binding site: evidence that cytoplasmic location of X protein is essential for gene transactivation. Hepatology 2001; 34: 1218-1224.
43. Nag A, Datta A, Yoo K, Bhattacharyya D, Chakrabortty A, Wang X, et al: DDB2 induces nuclear accumulation of the hepatitis B virus X protein independently of binding to DDB1. J Virol 2001; 75: 10383-10392.
44. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al: ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 2005; 24: 3470-3481.
45. Kim H, Lee H, Yun Y: X-gene product of hepatitis B virus induces apoptosis in liver cells. J Biol Chem 1998; 273: 381-385.
46. Schuster R, Gerlich WH, Schaefer S: Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts. Oncogene 2000; 19: 1173-1180.
47. Bromberg J: Stat proteins and oncogenesis. J Clin Invest 2002; 109: 1139-1142.
48. Campbell GS, Yu CL, Jove R, Carter-Su C: Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem 1997; 272: 2591- 2594.
49. Gamero AM, Young HA, Wiltrout RH: Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer? Cancer Cell 2004; 5: 111-112.
50. Waris G, Tardif KD, Siddiqui A: Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF- B and STAT-3. Biochem Pharmacol 2002; 64: 1425-1430.
51. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr: Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553-2558.
52. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al: SOCS-1, a negative regulator of the JAK/ STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001; 28: 29-35.
53. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, et al: SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 2005; 24: 6699-6708.